tbuckley/cabot-search huggingface dataset:
Gastrointestinal tract NK/t cell lymphoma: Clinical features, management, and prognosis of 47 patients.
Authors: Ming Jiang, Li qun Zou
Journal: Journal of Clinical Oncology (2012)

e18514 Background: The gastrointestinal tract is the most common primary sites of extranodal lymphomas, while gastrointestinal NK/T cell lymphomas (GINKT) are relatively rare. So far, the researches on this disease are few and the number of cases is small. In this article, we examined the clinical features andprognostic conditions of GINKT. Methods: A retrospective analysis was carried out on clinical data from 47 cases of confirmed GINKT. Results: Patients had a median age of 37 years. 35 cases were men (74.5%) and 12 cases were women (25.5%). The common clinical manifestations included fever (78.7%), abdominal pain (76.6%). Seventeen cases have intestinal perforation (36.2%). All patients showed ulcerative lesions, the most common site of involvement was the colon (27/47; 57.4%), followed by the jejunoileum and ileocecum (14/47; 29.8%). The median survival was 2.83(95% CI, 0.27–29) months. The log-rank univariate analysis showed older than 60 years, perforation, increased LDH level, high ECOG and NKIPI score, without chemotherapy, without surgery before perforation, late stage according to Musshoff or Lugano stage system had relatively poor prognoses. Cox multivariate analysis shown that age, perforation, B syndrome, stage according to Lugano system and surgery were independent prognostic risk factor for GINKT. Conclusions: GINKT is a rare type of lymphoma, is prone to perforation, hemorrhage and other complications, the prognosis is very poor. Lugano staging is a relatively suitable staging system. Surgery before Perforation is a key therapy factor which affected prognosis. Although values of chemotherapy and radiotherapy are unclear, combination therapy maybe is necessary.
Analysis of Correlation Between Weight at Diagnosis, Weight Gain After Breast Cancer Treatment and Recurrence in Women With Early Stage Breast Cancer (EBC)
Authors: P. Fedele, A. Nacci, A.M. Lapolla, L. Orlando, P. Schiavone, A. Marino, M. Cinefra, A. Ardizzone, M. De Pasquale, S. Cinieri
Journal: Annals of Oncology (2012)
Development of chronic kidney disease after acute kidney injury in patients with cirrhosis is common and impairs clinical outcomes
Authors: Octavi Bassegoda, Patricia Huelin, Xavier Ariza, Cristina Solé, Adrià Juanola, Jordi Gratacós-Ginès, Marta Carol, Isabel Graupera, Elisa Pose, Laura Napoleone, Sonia Albertos, Gloria de Prada, Marta Cervera, Javier Fernández, Núria Fabrellas, Esteban Poch, Elsa Solà, Pere Ginès
Journal: Journal of Hepatology (2020)
Reduced CYP2D6 Function Potentiates the Gefitinib-Induced Rash in Patients with Non-Small Cell Lung Cancer
Authors: T. Suzumura, T. Kimura, S. Kudoh, K. Umekawa, M. Nagata, Y. Kira, T. Nakai, K. Matsuura, N. Yoshimura, K. Hirata
Journal: Annals of Oncology (2012)
Towards Multidrug Adaptive Therapy
Authors: Jeffrey West, Li You, Jingsong Zhang, Robert A. Gatenby, Joel S. Brown, Paul K. Newton, Alexander R.A. Anderson
Journal: Cancer Research (2020)

A new ecologically inspired paradigm in cancer treatment known as "adaptive therapy" capitalizes on competitive interactions between drug-sensitive and drug-resistant subclones. The goal of adaptive therapy is to maintain a controllable stable tumor burden by allowing a significant population of treatment-sensitive cells to survive. These, in turn, suppress proliferation of the less-fit resistant populations. However, there remain several open challenges in designing adaptive therapies, particularly in extending these therapeutic concepts to multiple treatments. We present a cancer treatment case study (metastatic castrate-resistant prostate cancer) as a point of departure to illustrate three novel concepts to aid the design of multidrug adaptive therapies. First, frequency-dependent "cycles" of tumor evolution can trap tumor evolution in a periodic, controllable loop. Second, the availability and selection of treatments may limit the evolutionary "absorbing region" reachable by the tumor. Third, the velocity of evolution significantly influences the optimal timing of drug sequences. These three conceptual advances provide a path forward for multidrug adaptive therapy. SIGNIFICANCE: Driving tumor evolution into periodic, repeatable treatment cycles provides a path forward for multidrug adaptive therapy.
Long-Term Efficacy and Safety of L-BLP25 Vaccine in a Multi-Centre Open-Label Study of Patients with Unresectable Stage III NSCLC
Authors: C. Butts, R.N. Murray, C.J. Smith, P.M. Ellis, K. Jasas, A. Maksymiuk, G. Goss, M. Falk, A.H. Loos, D. Soulières
Journal: Annals of Oncology (2012)
Using High-Sensitivity Cardiac Troponin for the Exclusion of Inducible Myocardial Ischemia in Symptomatic Patients
Authors: Joan Walter, Jeanne du Fay de Lavallaz, Luca Koechlin, Tobias Zimmermann, Jasper Boeddinghaus, Ursina Honegger, Ivo Strebel, Raphael Twerenbold, Melissa Amrein, Thomas Nestelberger, Desiree Wussler, Christian Puelacher, Patrick Badertscher, Michael Zellweger, Gregor Fahrni, Raban Jeger, Christoph Kaiser, Tobias Reichlin, Christian Mueller
Journal: Annals of Internal Medicine (2020)

Background: The optimal noninvasive method for surveillance in symptomatic patients with stable coronary artery disease (CAD) is unknown. Objective: To apply a novel approach using very low concentrations of high-sensitivity cardiac troponin I (hs-cTnI) for exclusion of inducible myocardial ischemia in symptomatic patients with CAD. Design: Prospective diagnostic cohort study. (ClinicalTrials.gov: NCT01838148) Setting: University hospital. Patients: 1896 consecutive patients with CAD referred with symptoms possibly related to inducible myocardial ischemia. Measurements: Presence of inducible myocardial ischemia was adjudicated using myocardial perfusion imaging with single-photon emission computed tomography, as well as coronary angiography and fractional flow reserve measurements where available. Staff blinded to adjudication measured circulating hs-cTn concentrations. An hs-cTnI cutoff of 2.5 ng/L, derived previously in mostly asymptomatic patients with CAD, was assessed. Predefined target performance criteria were at least 90% negative predictive value (NPV) and at least 90% sensitivity for exclusion of inducible myocardial ischemia. Sensitivity analyses were based on measurements with an hs-cTnT assay and an alternative hs-cTnI assay with even higher analytic sensitivity (limit of detection, 0.1 ng/L). Results: Overall, 865 patients (46%) had inducible myocardial ischemia. The hs-cTnI cutoff of 2.5 ng/L provided an NPV of 70% (95% CI, 64% to 75%) and a sensitivity of 90% (CI, 88% to 92%) for exclusion of inducible myocardial ischemia. No hs-cTnI cutoff reached both performance characteristics predefined as targets. Similarly, using the alternative assays for hs-cTnI or hs-cTnT, no cutoff achieved the target performance: hs-cTnT concentrations less than 5 ng/L yielded an NPV of 66% (CI, 59% to 72%), and hs-cTnI concentrations less than 2 ng/L yielded an NPV of 68% (CI, 62% to 74%). Limitation: Data were generated in a large single-center diagnostic study using central adjudication. Conclusion: In symptomatic patients with CAD, very low hs-cTn concentrations, including hs-cTnI concentrations less than 2.5 ng/L, do not generally allow users to safely exclude inducible myocardial ischemia. Primary Funding Source: European Union, Swiss National Science Foundation, Kommission für Technologie und Innovation (Innosuisse), Swiss Heart Foundation, Cardiovascular Research Foundation Basel, University of Basel, University Hospital Basel, Roche, Abbott, and Singulex.
Genomic Evidence for Complex Domestication History of the Cultivated Tomato in Latin America
Authors: Hamid Razifard, Alexis Ramos, Audrey L Della Valle, Cooper Bodary, Erika Goetz, Elizabeth J Manser, Xiang Li, Lei Zhang, Sofia Visa, Denise Tieman, Esther van der Knaap, Ana L Caicedo
Journal: Molecular Biology and Evolution (2019)

The process of plant domestication is often protracted, involving underexplored intermediate stages with important implications for the evolutionary trajectories of domestication traits. Previously, tomato domestication history has been thought to involve two major transitions: one from wild Solanum pimpinellifolium L. to a semidomesticated intermediate, S. lycopersicum L. var. cerasiforme (SLC) in South America, and a second transition from SLC to fully domesticated S. lycopersicum L. var. lycopersicum in Mesoamerica. In this study, we employ population genomic methods to reconstruct tomato domestication history, focusing on the evolutionary changes occurring in the intermediate stages. Our results suggest that the origin of SLC may predate domestication, and that many traits considered typical of cultivated tomatoes arose in South American SLC, but were lost or diminished once these partially domesticated forms spread northward. These traits were then likely reselected in a convergent fashion in the common cultivated tomato, prior to its expansion around the world. Based on these findings, we reveal complexities in the intermediate stage of tomato domestication and provide insight on trajectories of genes and phenotypes involved in tomato domestication syndrome. Our results also allow us to identify underexplored germplasm that harbors useful alleles for crop improvement.
The Predictive Role of the 53BP1 Pathway in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients (P) Treated with First-Line Platinum-Based Chemotherapy
Authors: L. Bonanno, C. Costa, M. Majem, A. Gimenez-Capitan, I. Rodriguez, J.J. Sánchez, B. Massuti Sureda, A. Favaretto, M. Rugge, R. Rosell
Journal: Annals of Oncology (2012)
Therapy-Induced Senescence Drives Bone Loss
Authors: Zhangting Yao, Bhavna Murali, Qihao Ren, Xianmin Luo, Douglas V. Faget, Tom Cole, Biancamaria Ricci, Dinesh Thotala, Joseph Monahan, Jan M. van Deursen, Darren Baker, Roberta Faccio, Julie K. Schwarz, Sheila A. Stewart
Journal: Cancer Research (2020)

Abstract Chemotherapy is important for cancer treatment, however, toxicities limit its use. While great strides have been made to ameliorate the acute toxicities induced by chemotherapy, long-term comorbidities including bone loss remain a significant problem. Chemotherapy-driven estrogen loss is postulated to drive bone loss, but significant data suggests the existence of an estrogen-independent mechanism of bone loss. Using clinically relevant mouse models, we showed that senescence and its senescence-associated secretory phenotype (SASP) contribute to chemotherapy-induced bone loss that can be rescued by depleting senescent cells. Chemotherapy-induced SASP could be limited by targeting the p38MAPK-MK2 pathway, which resulted in preservation of bone integrity in chemotherapy-treated mice. These results transform our understanding of chemotherapy-induced bone loss by identifying senescent cells as major drivers of bone loss and the p38MAPK–MK2 axis as a putative therapeutic target that can preserve bone and improve a cancer survivor's quality of life. Significance: Senescence drives chemotherapy-induced bone loss that is rescued by p38MAPK or MK2 inhibitors. These findings may lead to treatments for therapy-induced bone loss, significantly increasing quality of life for cancer survivors.
Randomized, Open-Label Study of the Biological Effects of BLP25 Liposome (L-BLP25) Immunotherapy in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy: Sprint Study Design
Authors: T.J.M. Ruers, D. Aust, M. van den Eynde, G. Folprecht, J. Carrasco, M. Fuchs, J.M. Smit, A. Victor, S. Quaratino
Journal: Annals of Oncology (2012)
A Randomized, Controlled Phase III Trial of Docetaxel, Cisplatin and Fluorouracil (DCF) versus Cisplatin Plus Fluorouracil (CF) as First-Line Therapy in Chinese advanced Gastric Cancer
Authors: L. Shen, R. Xu, J. Wang, Y. Bai, T. Liu, S. Jiao, J. Xu, Y. Liu, N. Fan
Journal: Annals of Oncology (2012)
Cisplatin, Cyclophosphamide, Methotrexate, and 5-Fluorouracil (PCMF) as First Line Therapy of Metastatic Triple Negative Breast Cancer (MTNBC) in Patients Previously Treated with Adjuvant Anthracyclines and Taxanes: Retrospective Analysis
Authors: D.A. Donat
Journal: Annals of Oncology (2012)
Plans for same day emergency care are being “grossly derailed” by winter pressures
Authors: Gareth Iacobucci
Journal: BMJ (2020)

An NHS plan to provide urgent care to patients without admitting them to hospital to ease capacity problems this winter has been “grossly derailed” by trusts repurposing beds for patients being admitted, senior doctors have warned.

Last March, NHS England instructed every major hospital in England to provide same day emergency care—also known as ambulatory emergency care—in acute medical units by the end of the 2019 as part of the NHS’s long term plan.

The service is designed to offer an outpatient alternative to …
P1.17 High Rate of Genetic Abnormalities of Neoplastic Cells in Pseudofollicles of Cll
Authors: Z.B. Balogh, L. Reiniger, H. Rajnai, J. Csomor, A. Szepesi, A. Balogh, L. Deak, E. Gagyi, C. Bodor, A. Matolcsy
Journal: Annals of Oncology (2012)
Axitinib (AXI) and Everolimus (EVE) in the Treatment (TX) of Sunitinib-Refractory (SU-R) Patients (PTS) with Metastatic Renal Cell Carcinoma (MRCC): Results of a Simulated TX Comparison (STC) Analyses
Authors: I. Proskorovsky, A. Benedict, S. Negrier, J. Larkin, R. Sandin, C. Chen
Journal: Annals of Oncology (2012)
Sunitinib (SU) Dosing Schedule and Data Collection Timepoints: Impact on Quality of Life (QOL) Outcomes in Metastatic Renal Cell Carcinoma (MRCC)
Authors: A. Bushmakin, J.C. Cappelleri, B. Korytowsky, R. Sandin, E. Matczak, D. Cella
Journal: Annals of Oncology (2012)
A phase II multicenter trial of mFOLFOX6 as adjuvant treatment after resection of liver metastases from colorectal cancer (Miyagi-HBPCOG Trial-001): The final data of progression-free survival.
Authors: Yu Katayose, Kuniharu Yamamoto, Shinichi Takemura, Michinaga Takahashi, Ryuji Nakamura, Hiromune Shimamura, Taku Asanuma, Tetsuyuki Uchiyama, Kojin Endo, Masaya Oikawa, Kenichi Shiiba, Kei Nakagawa, Shinichi Egawa, Michiaki Unno
Journal: Journal of Clinical Oncology (2012)

e14011 Background: Perioperative chemotherapy with FOLFOX4 reduces the progression-free survival of patients with liver metastases from colorectal cancer. However, the benefit of adjuvant treatment after hepatectomy has not been clarified yet. Here, we evaluated the efficacy of treatment with mFOLFOX6 in a postoperative adjuvant setting. Methods: We recruited 49 patients from 17 hospitals (Japan) between July 2006 and June 2009 who were histologically proved to have colorectal cancer. The primary tumor had to be resected with R0 or R1 resection, and no detectable extrahepatic metastases. This report is the trial’s final data for progression-free survival (PFS) in all enrolled cases, while overall survival is still being monitored. The regimen was 12 cycle of mFOLFOX6. The primary endpoint was progression-free survival. This study was planned to detect a 20% increase in median PFS from 40% to 60% in all assigned patients based on the data of several previous surgeries, and the set of 50 cases. Results: 1 patient did not start the protocol treatment because liver metastases were detected before starting. 48 patients started the protocol treatment. 4 patients committed a protocol violation. Excluding this 4 violation cases from the 49 cases, 33 cases (75%) received 10 course (83.3%) of mFOLFOX6. The dose intensities of oxaliplatin, leucovorin, and 5-FU were 75.9%, 80.5%, 78%, respectively in all enrolled cases. The PFS at 2 years was 59.2%. The median survival time was 49 months. The PFS for single liver metastasis was better than that for multiple metastases (Wilcoxon test: p&lt;0.05). Overall survival was 72%. There were no Grade 4 adverse events (AE) or deaths related to chemotherapy. In Grade 3 AE, neutropenia, sensory disturbance, thrombocytopenia, and allergy were 37.5%, 8.3%, 8.3%, and 8.3%, respectively. Conclusions: Adjuvant treatment with mFOLFOX6 is feasible and could greatly improve the PFS without biologics. The benefit of this therapy with mFOLFOX6 as an adjuvant treatment needs to be evaluated further as compared to perioperative chemotherapy.
Clinical Activity of Crizotinib in Advanced Non-Small-Cell Lung Cancer (NSCLC) Harboring ROS1 Gene Rearrangement
Authors: Y.-J. Bang, S. Ou, D.R. Camidge, J.W. Clark, K. Wilner, L. Tye, P. Stephenson, M. Varella-Garcia, A.J. Iafrate, A.T. Shaw
Journal: Annals of Oncology (2012)
Chromatin interactome mapping at 139 independent breast cancer risk signals
Authors: Jonathan Beesley, Haran Sivakumaran, Mahdi Moradi Marjaneh, Luize G. Lima, Kristine M. Hillman, Susanne Kaufmann, Natasha Tuano, Nehal Hussein, Sunyoung Ham, Pamela Mukhopadhyay, Stephen Kazakoff, Jason S. Lee, Kyriaki Michailidou, Daniel R. Barnes, Antonis C. Antoniou, Laura Fachal, Alison M. Dunning, Douglas F. Easton, Nicola Waddell, Joseph Rosenbluh, Andreas Möller, Georgia Chenevix-Trench, Juliet D. French, Stacey L. Edwards
Journal: Genome biology (2020)

Genome-wide association studies have identified 196 high confidence independent signals associated with breast cancer susceptibility. Variants within these signals frequently fall in distal regulatory DNA elements that control gene expression.
Gender pay gap in general practice is 35%, report finds—owing to age, working hours, and partnerships
Authors: Elisabeth Mahase
Journal: BMJ (2020)

Female GPs earn an average of £40 000 (€47 000; $52 000) a year less than their male colleagues, an analysis of official NHS workforce data has found.1

A report by the Institute for Public Policy Research (IPPR) said that a male GP earned an estimated £110 000 a year on average, while female GPs earned an estimated £70 000. This represents a gender pay gap of 35% among GPs, which is the fifth largest pay gap of any UK profession as a percentage and is significantly higher than the …
Association of Genetic Polymorphisms in Tumor Suppressors, ERP29 and PTCH1, and DNA Transcription Factors, IKBKAP and ZNF415, with Cutaneous Melanoma Risk
Authors: E.F.D. Costa, G.J. Lourenço, C. Oliveira, J.A. Rinck-Junior, A.M. Moraes, G.A.S. Nogueira, C.S.P. Lima
Journal: Annals of Oncology (2012)
Gender reassignment: High Court to say whether NHS guidance on hormone blockers can be legally challenged
Authors: Clare Dyer
Journal: BMJ (2020)

The High Court in London has been asked to give the go ahead for a challenge to the legality of NHS guidelines on administering hormone blocking drugs to children at the UK’s only specialist NHS service for young people seeking gender reassignment.

Susan Evans, a former psychiatric nurse at the Tavistock and Portman NHS Foundation Trust’s gender identity development service (GIDS), and “Mrs A,” the mother of a 15 year old girl with autism who is on the service’s waiting list, have filed papers asking for a judicial review of the guidelines. They argue that the …
Deep Multilayer Brain Proteomics Identifies Molecular Networks in Alzheimer’s Disease Progression
Authors: Bing Bai, Xusheng Wang, Yuxin Li, Ping-Chung Chen, Kaiwen Yu, Kaushik Kumar Dey, Jay M. Yarbro, Xian Han, Brianna M. Lutz, Shuquan Rao, Yun Jiao, Jeffrey M. Sifford, Jonghee Han, Minghui Wang, Haiyan Tan, Timothy I. Shaw, Ji-Hoon Cho, Suiping Zhou, Hong Wang, Mingming Niu, Ariana Mancieri, Kaitlynn A. Messler, Xiaojun Sun, Zhiping Wu, Vishwajeeth Pagala, Anthony A. High, Wenjian Bi, Hui Zhang, Hongbo Chi, Vahram Haroutunian, Bin Zhang, Thomas G. Beach, Gang Yu, Junmin Peng
Journal: Neuron (2020)
MCPH1 (BRIT1) and Outcome to Erlotinib in Non-Small-Cell Lung Cancer (NSCLC) Patients (P) Harboring EGFR Mutations
Authors: R. Garcia-Campelo, J.J. Sánchez, C. Costa, C. Queralt, I. De Aguirre, M.A. Molina,, M. Majem, S. Cros, L. Capdevila, R. Rosell
Journal: Annals of Oncology (2012)
Clinical effectiveness of modified method of laparoscopic partial nephrectomy.
Authors: Sergey N Dimitriadi, Oleg Ivanovich Kit
Journal: Journal of Clinical Oncology (2013)

e15602 Background: Warm ischemia time (WIT) is the most important factor predicting postoperative renal function condition after laparoscopic partial nephrectomy (LPN). Methods: During 1 year (2012) 22 LPN was performed on T1 stage renal cell carcinoma (RCC) patients. Our current laparoscopic technique involves transperitoneal approach, atraumatic hilar clamping (in all patients), tumor excision by cold endoshears. In 12 cases (54.5%) pelvicaliceal system (PCS) of the kidney was opened. These patients underwent LPN modification, which consists of excluding of separate PCS suture repair of the kidney after tumor excision. This technique allowed reducing WIT. Tumor bed excision was sutured using “sliding clip” technique without using any addition hemostatic materials. Control group consist of 10 (45.5%) patients whose PCS were not opened during LPN. Results: Mean age in the main and control groups was 59.3±10.6 years (range 42-77) and 52.5±11.7 years (range 33-68), mean tumor size – 39.3±7.5 mm (range 29-57) and 39.5±7.5 mm (range 25-52), mean RENAL nephrometry sum - 7.6±1.2 (range 6-10) and 6.8±0.9 (range 5-8), mean WIT – 12.6±2.3 min.(range 9-16) and 11.3±3.1 (range 6-15), mean blood loss – 207.5±237.9 ml (range 50-800) and 97±32.7 ml (range 50-150) respectively. In all 12 cases PCS defect was up to 2 cm. Conversion was performed in one case with RENAL nephrometry sum 10 and one kidney lost due to complexity of resection. Mean follow up was 5.4±3.1 month (range 1-10). Intraoperative hemorrhage was in 2 main group patients. Delayed hemorrhage, urine leak, postoperative renal failure did not occur. All patients confirmed RCC, and all of them had negative inked surgical margins for cancer. Conclusions: Thus, use of modified technique of LPN allowed carrying out difficult partial nephrectomies (up to 10 RENAL nephrometry sum) with no significant deference of WIT (p=0.334 Mann Whithitney U-test) from more simple LPN (without opening PCS). This explains absence of kidney injury in the postoperative period. We suppose, that meticulous suture repair of a tumor bed using “sliding clip” technique with defects of PCS up to 2 cm is safe, considered urine leak development. This approach will allow to expand indications to LPN.
Bad publicity prompts US medical centers to take corrective action
Authors: Janice Hopkins Tanne
Journal: BMJ (2020)

Several US medical centers that were named and shamed last week in this year’s “Shkreli awards” have taken action to correct their criticized policies.

The awards are named after Martin Shkreli, who is now serving a seven year federal prison sentence for securities fraud. Previously, Shkreli was widely criticized when he gained rights to pyrimethamine, which is used to treat toxoplasmosis, and immediately raised its price from $13.50 (£10.40; €12.10) a pill to $750 a pill.1

The Shkreli awards are given by the Lown Institute, a nonprofit organization that aims to replace the current profit driven US healthcare system with “a just and caring system.” Vikas Saini, the institute’s president, told The BMJ that market forces led to the explosion of “money minded and [money] driven outrage of immoral practices and abuses” in healthcare.

The institute invites nominations for the awards through its newsletter, and the winners are selected by a panel of patient activists, clinicians, health policy experts, and journalists.2

Leading the 2019 Shkreli awards were six US medical centers that, the Lown Institute …